NEUROTOXICITY SCREENING

本合同的主要目标是建立 评估滥用药物的神经毒性或可能是 在治疗毒瘾方面的潜在益处。化合物须为 神经毒性评估将由NIDA提供。神经毒性 银幕(S)由此产生的努力将纳入敏感 神经化学和神经解剖学技术能够 评估影响单胺能系统和兴奋性毒素的毒性- 诱发的神经毒性。在开发此屏幕时，参考化合物 应用于评估技术的敏感性和可靠性 受雇的。啮齿动物和灵长类动物都将被用于这些研究。 初步研究将在啮齿类动物身上进行，但测试的全面评估 化合物将需要灵长类动物的研究。最初的化合物将是 评估的是伊波加因；最多可以评估两种额外的化合物 在本合同期间。对伊博加因的全面描述 对大鼠和灵长类动物都有神经毒性，包括二糖- 效果分析、作用地点，如果可能的话，还有作用机制。

The major objectives of this contract are to establish methods for evaluating the neurotoxicity of drugs of abuse or medications which may be of potential benefit in treating drug addiction. Compounds to be evaluated for neurotoxicity will be furnished by NIDA. The neurotoxicity screen(s) resulting from this effort will incorporate sensitive neurochemical and neuroanatomical techniques that are capable of evaluating toxicity affecting monoaminergic systems and excitotoxin- induced neurotoxicity. In developing this screen, reference compounds should be used to assess the sensitivity and reliability of the techniques employed. Both rodents and primates will be used in these studies. Initial studies will be conducted in rodents, but full evaluation of test compounds will require primate studies. The initial compound that will be evaluated is ibogaine; up to two additional compounds may be evaluated during the course of this contract. A full characterization of ibogaine's neurotoxicity in both rat and primate will be obtained, including diose- effects analysis, sites of action, and, if possible, mechanism of action.